Revenue Showdown: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.

Biotech Battle: Ionis vs. PTC Revenue Trends

__timestampIonis Pharmaceuticals, Inc.PTC Therapeutics, Inc.
Wednesday, January 1, 201421416100022963000
Thursday, January 1, 201528370300036766000
Friday, January 1, 201634662000082705000
Sunday, January 1, 2017507666000194392000
Monday, January 1, 2018599674000264734000
Tuesday, January 1, 20191123000000306980000
Wednesday, January 1, 2020729000000380766000
Friday, January 1, 2021810000000538593000
Saturday, January 1, 2022587000000698801000
Sunday, January 1, 2023787647000937822000
Monday, January 1, 2024705138000
Loading chart...

Unleashing insights

Revenue Showdown: Ionis Pharmaceuticals vs. PTC Therapeutics

In the competitive landscape of biotechnology, Ionis Pharmaceuticals and PTC Therapeutics have been vying for dominance over the past decade. Since 2014, Ionis Pharmaceuticals has consistently outperformed PTC Therapeutics in terms of revenue, with a notable peak in 2019 when Ionis's revenue surged to nearly double that of PTC. However, PTC Therapeutics has shown remarkable growth, increasing its revenue by over 400% from 2014 to 2023. By 2023, PTC's revenue reached approximately 94% of Ionis's, showcasing its rapid ascent in the industry. This rivalry highlights the dynamic nature of the biotech sector, where innovation and strategic advancements can significantly alter market positions. As both companies continue to innovate, the coming years promise further shifts in this intriguing revenue showdown.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025